Cargando…
Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.
Using a one-stage kinetic chromogenic assay, we studied the procoagulant activity (PCA) of prostatic tissue in an experimental model of prostate cancer in the rat. PCA was present in homogenates of rat prostate glands containing either benign or malignant tumours. The procoagulant activated factor X...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968672/ https://www.ncbi.nlm.nih.gov/pubmed/8297726 |
_version_ | 1782134791656701952 |
---|---|
author | Adamson, A. S. Luckert, P. Pollard, M. Snell, M. E. Amirkhosravi, M. Francis, J. L. |
author_facet | Adamson, A. S. Luckert, P. Pollard, M. Snell, M. E. Amirkhosravi, M. Francis, J. L. |
author_sort | Adamson, A. S. |
collection | PubMed |
description | Using a one-stage kinetic chromogenic assay, we studied the procoagulant activity (PCA) of prostatic tissue in an experimental model of prostate cancer in the rat. PCA was present in homogenates of rat prostate glands containing either benign or malignant tumours. The procoagulant activated factor X directly and was provisionally characterised as a tissue factor-factor VIIa complex. There was no significant differences in PCA between control rats and rats exposed to carcinogens that did not develop tumour. Levels in rats that developed tumours were significantly higher (P < 0.01) than all other groups and there was a positive correlation between tumour weight and PCA (r = 0.85, P < 0.001). Furthermore, prostatic PCA levels were higher in the metastasis (P < 0.02). We conclude that PCA reflects the malignant phenotype in this animals, the PCA of the primary tumour was compared with that of the corresponding secondary deposit and levels were higher in the metastasis (P < 0.02). We conclude that PCA reflects the malignant phenotype in this model of experimental prostate cancer and suggest that this parameter is worth evaluating as a potential tumour marker in the human disease. |
format | Text |
id | pubmed-1968672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1994 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19686722009-09-10 Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. Adamson, A. S. Luckert, P. Pollard, M. Snell, M. E. Amirkhosravi, M. Francis, J. L. Br J Cancer Research Article Using a one-stage kinetic chromogenic assay, we studied the procoagulant activity (PCA) of prostatic tissue in an experimental model of prostate cancer in the rat. PCA was present in homogenates of rat prostate glands containing either benign or malignant tumours. The procoagulant activated factor X directly and was provisionally characterised as a tissue factor-factor VIIa complex. There was no significant differences in PCA between control rats and rats exposed to carcinogens that did not develop tumour. Levels in rats that developed tumours were significantly higher (P < 0.01) than all other groups and there was a positive correlation between tumour weight and PCA (r = 0.85, P < 0.001). Furthermore, prostatic PCA levels were higher in the metastasis (P < 0.02). We conclude that PCA reflects the malignant phenotype in this animals, the PCA of the primary tumour was compared with that of the corresponding secondary deposit and levels were higher in the metastasis (P < 0.02). We conclude that PCA reflects the malignant phenotype in this model of experimental prostate cancer and suggest that this parameter is worth evaluating as a potential tumour marker in the human disease. Nature Publishing Group 1994-02 /pmc/articles/PMC1968672/ /pubmed/8297726 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Adamson, A. S. Luckert, P. Pollard, M. Snell, M. E. Amirkhosravi, M. Francis, J. L. Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. |
title | Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. |
title_full | Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. |
title_fullStr | Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. |
title_full_unstemmed | Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. |
title_short | Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. |
title_sort | procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968672/ https://www.ncbi.nlm.nih.gov/pubmed/8297726 |
work_keys_str_mv | AT adamsonas procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer AT luckertp procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer AT pollardm procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer AT snellme procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer AT amirkhosravim procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer AT francisjl procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer |